← Leaderboards
Nada Y. Kalaany
Boston Children'S Hospital
$4,073,738
Attributed
$4,073,738
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $524.5K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,073,738 · 2
By mechanism
R01$4,073,738 · 2
Top collaborators
No co-investigators on record.
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Morris F. White$23,937,236
- Umut Ozcan$7,002,515
- Sang Won Park$3,139,500
- Talal Amine Chatila$29,594,720
- Katharine Elaine D'aquino$155,166
Others in their field
Other Emerging Leaders on “Neoplastic Cell”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Zachary Scott Morris · University Of Wisconsin-Madison$6,108,830
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$6,006,178
- Gordon M Ringold · Quadriga Biosciences, Inc.$5,755,369
- Himisha Beltran · Dana-Farber Cancer Inst$5,409,904
Research focus
Neoplastic CellMetabolismIn VivoIn VitroMalignant NeoplasmsMetabolic PathwayCessation Of LifeGene ExpressionAffectInvestigationKras2 GeneMaintenanceMediatingMetabolicAreaCellsCultured CellsExperimental StudyCancer EtiologyCancer PatientGenetically Engineered MouseIncidenceKnock-DownPathway Interactions
Grant awards (9)
Role of Altered Nutrient Metabolism in Pancreatic Cancer$524,541
R01 · FY2025 · CA · contact PI
Role of Altered Nutrient Metabolism in Pancreatic Cancer$498,314
R01 · FY2024 · CA · contact PI
Role of Altered Nutrient Metabolism in Pancreatic Cancer$514,050
R01 · FY2023 · CA · contact PI
Role of Altered Nutrient Metabolism in Pancreatic Cancer$524,541
R01 · FY2022 · CA · contact PI
Role of Insulin Receptor Substrates in Kras-driven lung cancer$404,888
R01 · FY2021 · CA · contact PI
Role of Insulin Receptor Substrates in Kras-driven lung cancer$404,888
R01 · FY2020 · CA · contact PI
Role of Insulin Receptor Substrates in Kras-driven lung cancer$392,740
R01 · FY2019 · CA · contact PI
Role of Insulin Receptor Substrates in Kras-driven lung cancer$404,888
R01 · FY2018 · CA · contact PI
Role of Insulin Receptor Substrates in Kras-driven lung cancer$404,888
R01 · FY2017 · CA · contact PI